Belgium· BE-AMP-SAM594977-00
Voraxaze 1000 U
A glucarpidase product containing glucarpidase, registered in Belgium by Serb. The same ATC class is registered in 12 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Glucarpidase is registered in 12 of 19 countries.
Countries holding a registration under ATC V03AF09 (glucarpidase), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 8 of them publish a price we can compare per daily dose
Glucarpidase · ATC V03AF09
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Glucarpidase
- Manufacturer
- Serb
- Country
- Belgium (BE)
- ATC code
- V03AF09
- ATC class
- Glucarpidase
- Defined daily dose
- 3.5 TSD, E
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb4880324
- be_apb7742067
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
8 interactions on record for glucarpidase.
Graded by severity as the source publishes them — 8 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Glucarpidase · interactions on record
8 records
- 8 moderate
Most severe, free to view
- TrimethoprimJ01EA01moderate
- PemetrexedL01BA04moderate
- PralatrexateL01BA05moderate
- TrimetrexateP01AX07moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Glucarpidase in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomVoraxaze 1,000unit powder for solution for injection vialsProtherics Medicines Development Ltd
- SpainVORAXAZE 1.000 UNIDADES POLVO PARA SOLUCION INYECTABLESerb
- FinlandVoraxazeSerb
- FranceVORAXAZE 1000 unités, poudre pour solution injectableSERB
- IrelandVoraxaze 1,000 units powder for solution for injectionSerb S.A.S.
- IcelandVoraxazeSERB SAS
- Japanグルカルピダーゼ(遺伝子組換え)大原薬品工業
- NetherlandsVoraxaze 1000 IE/ml, poeder voor oplossing voor injectieSERB
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Voraxaze
- Liechtenstein · Voraxaze
- Norway · Voraxaze
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/95e2bd98-b6fc-431d-a64c-efa172a5cef3 GET /v1/drugs/95e2bd98-b6fc-431d-a64c-efa172a5cef3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder for solution for injection",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Voraxaze 1000 U",
"name_fr": "Voraxaze 1000 U",
"name_nl": "Voraxaze 1000 U",
"amp_code": "SAM594977-00",
"strengths": [
"1000.0000",
"1000.0000"
],
"pack_count": 1,
"substances": [
"Glucarpidase",
"Lactose"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Glucarpidase",
"authorisation_numbers": [
"EU/1/21/1586/001"
]
}See everything about glucarpidase.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.